Blue Jet Healthcare Q1 Profit Falls 17%, Stock Hits Lower Circuit

Mumbai, July 22 : Blue Jet Healthcare Ltd reported a 17.18% drop in net profit for the April–June quarter (Q1) of FY26. Profit fell to ₹91.1 crore from ₹110 crore in the previous quarter (January–March).

After the earnings report, the company’s shares dropped 10% and closed at ₹906.15 on the National Stock Exchange (NSE).

Company expenses rose sharply by 16.89% to ₹240.1 crore. However, revenue from operations increased by 4.2% to ₹354.7 crore, up from ₹340.4 crore last quarter.

Total income also went up slightly by 2.95% to ₹363 crore.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) for the quarter was ₹121 crore, showing a 13.1% decline from the last quarter. The EBITDA margin also dropped by more than 700 basis points quarter-on-quarter. However, both EBITDA and margin were better than the same period last year.

In the past five days, Blue Jet’s stock has fallen ₹66.75 or 6.86%. Still, it has gained ₹49.9 (5.83%) over the last month and ₹347.4 (62.17%) in the past six months. Since January 2025, the stock is up by 57%.

Blue Jet Healthcare’s Managing Director, Shiven Arora, said the quarterly performance was driven by growth in its PI (pharmaceutical intermediates) and API (active pharmaceutical ingredients) segments. He remains confident about the company’s future.

He said the company’s growth strategy is based on expanding production, strong research and development (R&D), and a strong pipeline of high-value products. “We aim to deliver long-term value through consistent performance, innovation, and smart investments,” Arora added.

Blue Jet Healthcare is a specialty pharma and healthcare ingredients company. It works as a Contract Development and Manufacturing Organisation (CDMO) and makes contrast media intermediates and sweeteners. Clients include GE Healthcare, Colgate Palmolive (India), Unilever, and others.